ASCEND Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • ASCEND Therapeutics's estimated annual revenue is currently $42.4M per year.(i)
  • ASCEND Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • ASCEND Therapeutics has 211 Employees.(i)

ASCEND Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Commercial OperationsReveal Email/Phone
3
Executive Director, Regulatory Affairs and Quality AssuranceReveal Email/Phone
4
Associate Director, Trade and Market AccessReveal Email/Phone
5
Sr. Director, MarketingReveal Email/Phone
6
Senior Director Human ResourcesReveal Email/Phone
7
Associate Manager, Training and DevelopmentReveal Email/Phone
8
District ManagerReveal Email/Phone
9
Senior Manager, Medical AffairsReveal Email/Phone
10
Sr. Manager, Compliance & QualityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.5M21-12%$1.8MN/A
Add Company

What Is ASCEND Therapeutics?

ASCEND Therapeutics is a biopharmaceutical company focused on the research, development and use of transdermal drug delivery technology to overcome therapeutic barriers and raise the standard of care for previously unmet chronic health conditions. Founded in 2002 and based in Herndon, VA, ASCEND uses its proprietary percutaneous hydroalcoholic gel technology to deliver therapy in instances where oral delivery is impossible or undesirable

keywords:N/A

N/A

Total Funding

211

Number of Employees

$42.4M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

ASCEND Therapeutics News

2022-04-17 - Hormone Replacement Therapy Market Is Set to Expand at a ...

... Tolmar Pharmaceuticals, Inc., Novartis AG, Upsher-Smith Laboratories Inc., SottoPelle, Neuva Aesthetics, Ascend Therapeutics.

2022-04-13 - Assessing Higher Dose Nusinersen in Patients With SMA

Basil Darras, MD, offered his perspective on the ASCEND study ... to another approved therapy, risdiplam (Evrysdi; PTC Therapeutics).

2022-03-22 - Axsome Therapeutics to Acquire Sunosi® from Jazz ...

NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, ... the potential for the ASCEND clinical trial, combined with the GEMINI...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35.6M2235%N/A
#2
$35M227-8%N/A
#3
$37.1M2388%$77.1M
#4
$85.8M240-10%N/A
#5
$39.2M2460%N/A